Search

Your search keyword '"Pilette, C"' showing total 510 results
Start Over Author "Pilette, C"
510 results on '"Pilette, C"'

2. Characterization of Small Airway Obstruction Diversity in COPD

Author

Geudens, V., primary, De Fays, C., additional, Willems, L., additional, Vermaut, A., additional, Aerts, G., additional, Kerckhof, P., additional, Goos, T., additional, Kaes, J., additional, Hooft, C., additional, Jin, X., additional, Beeckmans, H., additional, Khaled Mohamed Elm Mohamady, Y., additional, Aversa, L., additional, Vermant, M., additional, Gyselinck, I., additional, Verhaegen, J., additional, Van Slambrouck, J., additional, Aelbrecht, C., additional, Higham, A., additional, Cortesi, E., additional, Vanstapel, A., additional, McDonough, J.E., additional, Carlon, M.S., additional, Quarck, R., additional, Boone, M., additional, Dupont, L., additional, Weynand, B., additional, Pilette, C., additional, Van Raemdonck, D.E., additional, Ceulemans, L.J., additional, Hogg, J.C., additional, Hackett, T.-L., additional, Vos, R., additional, Wuyts, W.A., additional, Janssens, W., additional, Vanaudenaerde, B., additional, and Gayan-Ramirez, G., additional

Published
2024
Full Text
View/download PDF

3. Impact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study

Author

Liu, M.C., primary, Chaudhuri, R., additional, Chupp, G.L., additional, Heaney, L.G., additional, Lee, J.K., additional, Pilette, C., additional, Brusselle, G., additional, Alfonso Cristancho, R., additional, Zhang, L., additional, and Howarth, P., additional

Published
2024
Full Text
View/download PDF

5. Retour triomphant des J2R 2023 à Tours : un tourbillon d’échanges scientifiques et d’émotion

Author

Annesi-Maesano, I., primary, Bonniaud, P., additional, Bouchaud, G., additional, Boyer, L., additional, Gazzeri, S., additional, Gosset, P., additional, Gras, D., additional, Guibert, C., additional, Guignabert, C., additional, Mari, B., additional, Matecki, S., additional, Morélot, C., additional, Pilette, C., additional, Planes, C., additional, Plantier, L., additional, Polette, M., additional, Si-Tahar, M., additional, Taillé, C., additional, and Vachier, I., additional

Published
2024
Full Text
View/download PDF

9. A Belgian survey on the diagnosis of asthma–COPD overlap syndrome

Author

Cataldo D, Corhay JL, Derom E, Louis R, Marchand E, Michils A, Ninane V, Peché R, Pilette C, Vincken W, and Janssens W

Subjects
ACOS, airway obstruction, asthma, COPD, diagnosis, inhaled corticosteroids., Diseases of the respiratory system, RC705-779
Abstract

Didier Cataldo,1 Jean-Louis Corhay,1 Eric Derom,2 Renaud Louis,1 Eric Marchand,3,4 Alain Michils,5 Vincent Ninane,6 Rudi Peché,7 Charles Pilette,8 Walter Vincken,9 Wim Janssens10 1Department of Respiratory Diseases, CHU Liège, University of Liège, Liège, 2Department of Respiratory Medicine, Ghent University Hospital, Ghent, 3Department of Respiratory Medicine, CHU – UCL – Namur, Université catholique de Louvain, Yvoir, 4Molecular Physiology Research Unit (URPhyM)-NARILIS, Laboratory of General Physiology, University of Namur, Namur, 5Chest Department, Erasme University Hospital, Université Libre de Bruxelles, Brussels, 6Department of Respiratory Medicine, University Hospital Saint-Pierre, Université Libre de Bruxelles, Brussels, 7Department of Respiratory Medicine, University Hospital Vésale, Montigny-le-Tilleul, 8Department of Respiratory Medicine, Cliniques universitaires St Luc, Université Catholique de Louvain, Brussels, 9Respiratory Division, University Hospital Brussels (UZ Brussel), Vrije Universiteit Brussel, Brussels, 10Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium Introduction: Patients with chronic airway disease may present features of both asthma and COPD, commonly referred to as asthma–COPD overlap syndrome (ACOS). Recommendations on their diagnosis are diffuse and inconsistent. This survey aimed to identify consensus on criteria for diagnosing ACOS.Methods: A Belgian expert panel developed a survey on ACOS diagnosis, which was completed by 87 pulmonologists. Answers chosen by ≥70% of survey respondents were considered as useful criteria for ACOS diagnosis. The two most frequently selected answers were considered as major criteria, others as minor criteria. The expert panel proposed a minimal requirement of two major criteria and one minor criterion for ACOS diagnosis. Respondents were also asked which criteria are important for considering inhaled corticosteroids prescription in a COPD patient.Results: To diagnose ACOS in COPD patients, major criteria were “high degree of variability in airway obstruction over time (change in forced expiratory volume in 1 second ≥400 mL)” and “high degree of response to bronchodilators (>200 mL and ≥12% predicted above baseline)”. Minor criteria were “personal/family history of atopy and/or IgE sensitivity to ≥1 airborne allergen”, “elevated blood/sputum eosinophil levels and/or increased fractional exhaled nitric oxide”, “diagnosis of asthma 40 years”; “emphysema on chest computed tomography scan”.Conclusion: Specific criteria were identified that may guide physicians to a more uniform diagnostic approach for ACOS in COPD or asthma patients. These criteria are largely similar to those used to prescribe inhaled corticosteroids in COPD. Keywords: ACOS, airway obstruction, asthma, COPD, diagnosis, inhaled corticosteroids

Published
2017

11. Morphometrics and Mucosal Immune Features in Lungs With End-stage Chronic Obstructive Pulmonary Disease

Author

De Fays, C., primary, Beeckmans, H., additional, Kerckhof, P., additional, Geudens, V., additional, Vermaut, A., additional, Gyselinck, I., additional, Goos, T., additional, Vermant, M., additional, Kaes, J., additional, Van Slambrouck, J., additional, Mohamady, Y., additional, Willems, L., additional, Aversa, L., additional, Maes, K., additional, Aelbrecht, C., additional, Everaerts, S., additional, Mcdonough, J.E., additional, De Sadeleer, L.J., additional, Gohy, S., additional, Ambroise, J., additional, Wuyts, W.A., additional, Janssens, W.L.H., additional, Ceulemans, L.J., additional, Van Raemdonck, D.E.M., additional, Vos, R., additional, Hackett, T.-L., additional, Hogg, J.C., additional, Kaminski, N., additional, Pilette, C., additional, Gayan-Ramirez, G., additional, and Vanaudenaerde, B., additional

Published
2023
Full Text
View/download PDF

13. (293) Altered Pigr/Iga Mucosal Immunity in Bronchiolitis Obliterans Syndrome

Author

Carlier, F.M., primary, Pretolani, M., additional, Detry, B., additional, Planté-Bordeneuve, T., additional, Longchampt, E., additional, Falque, L., additional, Reynaud-Gobert, M., additional, Hirschi, S., additional, Demant, X., additional, Mornex, J., additional, Tissot, A., additional, Pavec, J. Le, additional, Bunel-Gourdy, V., additional, Foureau, A., additional, Vallée, A., additional, Pilette, C., additional, and Brugière, O., additional

Published
2023
Full Text
View/download PDF

19. Altered pIgR/IgA mucosal immunity in bronchiolitis obliterans syndrome

Author

Carlier, F., primary, Pretolani, M., additional, Detry, B., additional, Heddebaut, N., additional, Planté-Bordeneuve, T., additional, Longchampt, E., additional, Falque, L., additional, Reynaud-Gaubert, M., additional, Hirschi, S., additional, Demant, X., additional, Mornex, J., additional, Tissot, A., additional, Le Pavec, J., additional, Messika, J., additional, Foureau, A., additional, Vallée, A., additional, Pilette, C., additional, and Brugière, O., additional

Published
2023
Full Text
View/download PDF

20. L’impact de la comorbidité des polypes nasaux sur l’efficacité en vraie vie du mépolizumab chez les patients souffrant d’asthme sévère : résultats de l’étude REALITI-A

Author

Liu, M.C., primary, Bagnasco, D., additional, Matucci, A., additional, Pilette, C., additional, Price, R.G., additional, Aoife-Maxwell, A.C., additional, Alfonso-Cristancho, R., additional, Jakes, R.W., additional, Yang, S., additional, Howarth, P., additional, Cheema, A.S., additional, and Iaz-Chachaut, L., additional

Published
2023
Full Text
View/download PDF

22. [Potential therapeutic implication of focal adhesion kinase in small-cell lung cancer]

Author

Decouvreur, C, Lecocq, M, Pilette, C, Aboubakar Nana, F, Ocak, Sebahat, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service de pneumologie

Subjects
Mice, Lung Neoplasms, Inhibiteur de tyrosine kinase, Cell Movement, Focal Adhesion Protein-Tyrosine Kinases, Kinase de l’Adhérence Focale, Tyrosine kinase inhibitor, Animals, Humans, Cancer pulmonaire à petites cellules, Small Cell Lung Carcinoma, Small-cell lung cancer, Focal Adhesion Kinase
Abstract

The molecular steps leading to small cell lung cancer (SCLC) development and progression are still poorly understood, resulting in the absence of targeted therapy and an extremely poor prognosis. Activation of Focal Adhesion Kinase (FAK) plays a key role in the invasive behavior of this cancer in vitro. Our hypothesis is that FAK could be a therapeutic target in SCLC. Our work aims to describe a mouse model to study the role of FAK and the antitumoral potential of its inhibition in SCLC in vivo.

Published
2023

23. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

Author

Menzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T., Jackson, D. J., Price, D., Lugogo, N., Kreindler, J., Burden, A., de Giorgio-Miller, A., Faison, S., Padilla, K., Martin, U. J., Gil, E. G., Ardusso, L., Bazerque, R. F., Doreski, P. A. C., Elias, P. C., Gattolin, G., Medina, A. C., Ruiz, X. B., Salvado, A., Del Olmo Sansone, R. A., Wehbe, L., Verra, F. J. B., Brusselle, G., Pilette, C., Martinot, J. -B., Antila, M. A., Blanco, D. C., Cerci, A., Cunha, T. M., Fiss, E., Franza, L., Machado, A. S., De Mattos, W. L. L. D., Grava, S., Minamoto, S. E. T., De Oliveira, C. A., Cheema, A. S., Dorscheid, D., Fera, T. A. E., Gagnon, R., Philteos, G., Sussman, G., Yang, W. H. -C., Aguilar, C. D., Jaller, R., Jazime, M. L., Serrano, F. O., Vanegas, A. C., Vargas, L. K., Villegas, M. F., Hilberg, O., Nielsen, H. B., Nielsen, J., Weinreich, U. M., Ulrik, C. S., Adam, S. M., Deslee, G., Pegliasco, H., Pradelli, J., Roux, P. -M., Russier, M., Deckelmann, R., Eich, A., Forster, A., Herth, F., Kirschner, J., Kirsten, A. -M., Schuhmann, M., Schultz, T. K., Ludwig-Sengpiel, A., Teber, I., Zimmermann, G. S., Almerigogna, F., Celi, A., Paggiaro, P., D'Amato, M., Palange, P., Pirina, P., Spanevello, A., Colin, D. D. H., Hernandez, A. R., Garcia, E. A. R., Gonzalez, E. M., Terrones, R. A. R., Javier, R. C., Suarez, J. F. R., Cheimihska, M., Cudzik, K., Olech-Cudzik, A., Filipek, K., Golinski, L., Kwasniewski, A., Madra-Rogacka, D., Mroz, R., Nittner-Marszalska, M., Pawlukiewicz, M., Lekarska, P. P., Pioszczuk, A., Springer, E., Swiderska, A., Zurowska-Gebala, M., Emelyanov, A. V., Kurbacheva, O., Odegova, A., Peskov, A., Petrov, D. V., Rubanik, T. V., Vasilev, M., Vershinina, M., Barcala, F. J. G., Blanco, V. R., Fernandez, A. M. P., Fernandez, C. G., Garcia, J. M. I., Munoz, A. V. A., Ramos, C. C., Sanz, C. C., Bjermer, L., Chen, C. -Y., Fang, W. -F., Hang, L. -W., Hsu, J. -Y., Kuo, H. -P., Lee, K. -Y., Shen, S. -Y., Sheu, C. -C., Gore, R., Saralaya, D., Alpizar, S. A., Bansal, S., Ismail, H., Kaelin, T. D., Koura, F., Lee, M. D., Maddipati, V., Malur, A., Mcevoy, C. E., Mehta, H., Mohan, A., Moore, W. C., Krings, J., Pippins, A., Deaton, I., Hmieleski, B., Field, P., Reibman, J., Siri, D. D., Sumino, K., Swenson, C., Tilley, S. L., Villareal, M., Pulmonology, and Pulmonary medicine

Subjects
Pulmonary and Respiratory Medicine, Adrenal Cortex Hormones, Humans, Anti-Asthmatic Agents, Recovery of Function, Asthma, Adrenal Insufficiency
Abstract

BackgroundOral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day−1(median (range) 0.0 (0.0–40.0) mg).MethodsThe maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ∼6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events.Results598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0–40.0) mg), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (–19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports.ConclusionsMost patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.

Published
2022

25. Altered pIgR/IgA mucosal immunity in bronchiolitis obliterans syndrome

Author

Carlier, F, Pretolani, M, Detry, B, Heddebaut, N, Planté-Bordeneuve, T, Longchampt, E, Falque, L, Reynaud-Gaubert, M, Hirschi, S, Demant, X, Mornex, J, Tissot, A, Le Pavec, J, Messika, J, Foureau, A, Vallée, A, Pilette, C, Brugière, O, The Colt Consortium, and UCL - (MGD) Service de pneumologie

Abstract

Aims: Long-term survival after lung transplantation (LT) is hampered by the occurrence of chronic lung allograft dysfunction (CLAD), manifesting as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS). CLAD is triggered by several factors, e.g. recurrent infections. As immunoglobulin (Ig) A is crucial to ensure mucosal immunity and limit airway microbial load, we explored whether IgA and its epithelial receptor, the polymeric Ig receptor (pIgR) are impaired in BOS. Methods: Bronchoalveolar lavages (BAL, n=120) from LT recipients included in the Cohort for Lung Transplantation were collected at pre-defined timepoints prior to the diagnosis of functional stability (BOS-free, n=30) or BOS (pre-BOS, n=30), and assessed for secretory (S)-IgA. Bronchiolar epithelium pIgR expression was quantified in transbronchial biopsies from BOS-free (n=20), pre-BOS (n=19) and BOS LT recipients (n=12), as well as in end-stage BOS explants (n=15). Results: S-IgA levels were reduced in BAL from pre-BOS LT recipients versus BOS-free (16.1 vs 33.4 µg/ml, p

Published
2022

27. Terminal bronchioles decrease before emphysematous destruction and adaptive immune response in human explant lungs with COPD

Author

de Fays, C, primary, Beeckmans, H, additional, Kerckhof, P, additional, Geudens, V, additional, Vermaut, A, additional, Gyselinck, I, additional, Goos, T, additional, Vermant, M, additional, Kaes, J, additional, Aelbrecht, C, additional, Maes, K, additional, Mohamady, Y, additional, Aversa, L, additional, Everaerts, S, additional, Mcdonough, J E, additional, De Sadeleer, L J, additional, Gohy, S, additional, Ambroise, J, additional, Wuyts, W A, additional, Janssens, W, additional, Ceulemans, L J, additional, Van Raemdonck, D E, additional, Vos, R, additional, Kaminski, N, additional, Pilette, C, additional, Gayan-Ramirez, G, additional, and Vanaudenaerde, B M, additional

Published
2022
Full Text
View/download PDF

28. Airway remodeling in COVID-19 lungs

Author

Geudens, V, primary, Van Slambrouck, J, additional, Aerts, G, additional, Willems, L, additional, Goos, T, additional, Kaes, J, additional, Gyselinck, I, additional, Aelbrecht, C, additional, Vermaut, A, additional, Beeckmans, H, additional, Vermant, M, additional, De Fays, C, additional, Sacreas, A, additional, Aversa, L, additional, Verstraete, K, additional, Orlitová, M, additional, Vanstapel, A, additional, E. Mcdonough, J, additional, Pilette, C, additional, Janssens, W, additional, A. Wuyts, W, additional, M. Verleden, G, additional, E. Van Raemdonck, D, additional, Vos, R, additional, Gayan-Ramirez, G, additional, J. Ceulemans, L, additional, and M. Vanaudenaerde, B, additional

Published
2022
Full Text
View/download PDF

29. An in depth study of morphological small airway changes in explant lungs with end stage COPD

Author

de Fays, C, primary, Geudens, V, additional, Beeckmans, H, additional, Vermaut, A, additional, Gyselinck, I, additional, Goos, T, additional, Vermant, M, additional, Kaes, J, additional, Aelbrecht, C, additional, Maes, K, additional, Mohamady, Y, additional, Willems, L, additional, Aversa, L, additional, Everaerts, S, additional, Mcdonough, J E, additional, De Sadeleer, L, additional, Gohy, S, additional, Wuyts, W A, additional, Janssens, W, additional, Ceulemans, L J, additional, Van Raemdonck, D E, additional, Vos, R, additional, Pilette, C, additional, Gayan-Ramirez, G, additional, and Vanaudenaerde, B M, additional

Published
2022
Full Text
View/download PDF

30. Altered pIgR/IgA mucosal immunity in bronchiolitis obliterans syndrome

Author

UCL - (MGD) Service de pneumologie, Carlier, F, Pretolani, M, Detry, B, Heddebaut, N, Planté-Bordeneuve, T, Longchampt, E, Falque, L, Reynaud-Gaubert, M, Hirschi, S, Demant, X, Mornex, J, Tissot, A, Le Pavec, J, Messika, J, Foureau, A, Vallée, A, Pilette, C, Brugière, O, The Colt Consortium, UCL - (MGD) Service de pneumologie, Carlier, F, Pretolani, M, Detry, B, Heddebaut, N, Planté-Bordeneuve, T, Longchampt, E, Falque, L, Reynaud-Gaubert, M, Hirschi, S, Demant, X, Mornex, J, Tissot, A, Le Pavec, J, Messika, J, Foureau, A, Vallée, A, Pilette, C, Brugière, O, and The Colt Consortium

Abstract

Aims: Long-term survival after lung transplantation (LT) is hampered by the occurrence of chronic lung allograft dysfunction (CLAD), manifesting as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS). CLAD is triggered by several factors, e.g. recurrent infections. As immunoglobulin (Ig) A is crucial to ensure mucosal immunity and limit airway microbial load, we explored whether IgA and its epithelial receptor, the polymeric Ig receptor (pIgR) are impaired in BOS. Methods: Bronchoalveolar lavages (BAL, n=120) from LT recipients included in the Cohort for Lung Transplantation were collected at pre-defined timepoints prior to the diagnosis of functional stability (BOS-free, n=30) or BOS (pre-BOS, n=30), and assessed for secretory (S)-IgA. Bronchiolar epithelium pIgR expression was quantified in transbronchial biopsies from BOS-free (n=20), pre-BOS (n=19) and BOS LT recipients (n=12), as well as in end-stage BOS explants (n=15). Results: S-IgA levels were reduced in BAL from pre-BOS LT recipients versus BOS-free (16.1 vs 33.4 µg/ml, p<0.01). pIgR bronchiolar expression was reduced in transbronchial biopsies from BOS (p<0.05 vs BOS-free and pre-BOS), with further decrease in end-stage BOS explants (p<0.0001 vs BOS-free and pre-BOS). Conclusions: BAL S-IgA and pIgR decreased levels suggest that the pIgR/IgA system is impaired in BOS. This could play a pathogenic role by increasing susceptibility to local infections.

Published
2022

38. RESPIRenT : RESeau de Pneumologie en Innovation et Recherche translaTionnelle, un nouveau souffle pour les J2R

Author

Annesi-Maesano, I., primary, Bonniaud, P., additional, Bouchaud, G., additional, Boyer, L., additional, Gazzeri, S., additional, Gosset, P., additional, Gras, D., additional, Guibert, C., additional, Guignabert, C., additional, Mari, B., additional, Matecki, S., additional, Morélot, C., additional, Pilette, C., additional, Planes, C., additional, Plantier, L., additional, Polette, M., additional, Si-Tahar, M., additional, Taillé, C., additional, and Vachier, I., additional

Published
2022
Full Text
View/download PDF

39. Étude prospective internationale en vie réelle du mépolizumab chez les patients souffrant d’asthme sévère à un an: REALITI-A

Author

Pilette, C., primary, Canonica, G.W., additional, Chaudhuri, R., additional, Lee, F.E.H., additional, Lee, J.K., additional, Almonacid Sanchez, C., additional, Alfonso-Cristancho, R., additional, Jakes, R., additional, Maxwell, A., additional, Price, R., additional, Howarth, P., additional, and Chemla Seydoux, S., additional

Published
2022
Full Text
View/download PDF

46. Tonnerre de Brest ! Des Journées de Recherche Respiratoires 2020 pas comme les autres…

Author

Annesi-Maesano, I., Bonniaud, P., Bouchaud, G., Boyer, L., Frossard, N., Gazzeri, S., Gosset, P., Gras, D., Guibert, C., Guignabert, C., Mari, B., Matecki, Stefan, Morelot, C., Pilette, C., Planes, C., Plantier, L., Polette, M., Si-Tahar, Mustapha, Taillé, C., Vachier, I., Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire d'Innovation Thérapeutique (LIT), Université de Strasbourg (UNISTRA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Sorbonne Université - Faculté de médecine [CHU Pitié Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Faculté de Médecine et Médecine Dentaire [UCLouvain], Université Catholique de Louvain = Catholic University of Louvain (UCL), Groupe Hospitalier Universitaire Paris Seine-Saint-Denis (GHUPSSD), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), UFR Médecine [Santé] - Université Paris Cité (UFR Médecine UPCité), Université Paris Cité (UPCité), and CHU Montpellier

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Tentons un peu d’oublier l’année 2020, mais pas complètement . . . C’est une année qui nousaura conduits à des envies et des visions différentes. Les rencontres conviviales et bien-veillantes qui ponctuent nos journées chaque année au mois d’octobre depuis 2005 n’ontpu se dérouler comme prévues, mais nous étions tous présents pour les 16esJournées deRecherche Respiratoire (J2R) le 16 octobre 2020, bien que devant nos écrans !Nous y avons cru jusqu’au bout et pensions pouvoir bénéficier de la fin de la fenêtreestivale, le programme était prêt et nos hôtes Brestois (nous ne remercierons jamais assezles équipes des Prs Francis Couturaud et Christophe Leroyer) avaient pensé à toutes lessolutions pour maintenir la distanciation, mais force fut de constater fin septembre qu’iln’était plus réaliste de poursuivre l’aventure en présentiel !!!Qu’à cela ne tienne, le plus important était de permettre aux jeunes, dont les résumésavaient suscité suffisamment d’intérêt et d’appétit pour une communication orale, deprésenter leurs travaux. Les J2R 2020 seraient donc organisées en format virtuel. Noustenons à remercier la SPLF pour son soutien logistique qui a permis cette transformation,ainsi que nos sponsors qui nous permettent de faire vivre les J2R depuis 16 ans.C’est ainsi que nos 19 jeunes étudiants chercheurs ont présenté et discuté leurs travauxsous forme de communications orales lors du Webinaire J2R. Tous les thèmes étaient repré-sentés (asthme, BPCO, cancer bronchique, maladies vasculaires, maladies inflammatoirespulmonaires, infectiologie, épidémiologie et la physiologie. . .) et ces communications,comme à l’accoutumée d’excellente qualité, ont pu être écoutées par quelques 135 per-sonnes connectées. Merci à tous des efforts consentis qui ont permis ce succès.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results